11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer

Reference

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA: A Cancer J Clin. 2006;56(2):106–130.
   PubMed Web of Science ®Google Scholar
• Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S. et al. Stratification of high-risk prostate cancer into prognostic categories: A European multiinstitutional study. Eur Urol. 2015;67:157–64. https://doi.org/10.1016/j.eururo.2014.01.020 PMID:24486307
   PubMed Web of Science ®Google Scholar
• Ubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578–583. https://doi.org/10.1053/hp.2000.6698 PMID:10836297
   PubMed Web of Science ®Google Scholar
• Parker WP, Davis BJ, Park SS, Olivier KR, Choo R, Nathan MA. et al. Identification of Site-specific recurrence following primary radiation therapy for prostate cancer using C-11 choline positron emission tomography/computed tomography: A nomogram for predicting extrapelvic disease. Eur Urol. 2017;71(3):340–8. https://doi.org/10.1016/j.eururo.2016.08.055
   PubMed Web of Science ®Google Scholar
• Hellman S, Weichselbaum R. Oligometastases. J. Clin. Oncol. 1995;13:8–10. https://doi.org/10.1200/JCO.1995.13.1.8 PMID:7799047
   PubMed Web of Science ®Google Scholar
• Weichselbaum R, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011 Jun;8(6):378–82. https://doi.org/10.1038/nrclinonc.2011.44 PMID:21423255
   PubMed Web of Science ®Google Scholar
• MacDermed D, Weichselbaum R, Salama J. A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol. 2008;98(3):202–6. https://doi.org/10.1002/jso.21102 PMID:18618604
   PubMed Web of Science ®Google Scholar
• Cattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M. et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423–9. https://doi.org/10.1016/j.eururo.2007.03.032 PMID:17397992
   PubMed Web of Science ®Google Scholar
• Schwarzenböck S, Souvatzoglou M, Krause BJ. Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. Theranostics. 2012;2(3):318–30. https://doi.org/10.7150/thno.4008 PMID:22448198
   PubMed Web of Science ®Google Scholar
• Fanti S, Minozzi S, Castellucci P, Balduzzi S, Herrmann K, Krause BJ, Oyen W, Chiti A. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging. 2016;43(1):55–69. https://doi.org/10.1007/s00259-015-3202-7
   PubMed Web of Science ®Google Scholar
• Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, Nader M, Gruy B, Janetschek G, Langsteger W. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254(3):925–33. https://doi.org/10.1148/radiol.09090413
   PubMed Web of Science ®Google Scholar
• Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ. et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67(5):852–63. https://doi.org/10.1016/j.eururo.2014.09.004
   PubMed Web of Science ®Google Scholar
• Tree A, Khoo V, Eeles R, Ahmed M, Dearnaley D, Hawkins M, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28–37. https://doi.org/10.1016/S1470-2045(12)70510-7 PMID:23276369
   PubMed Web of Science ®Google Scholar
• Franzese C, Cozzi L, Franceschini D, D'Agostino G, Comito T, De Rose F, et al. Role of stereotactic body radiation therapy with volumetric-modulated arcs and high-intensity photon beams for the treatment of abdomino-pelvic lymph-node metastases. Cancer Invest. 2016;34(7):348–54. https://doi.org/10.1080/07357907.2016.1197235
   PubMed Web of Science ®Google Scholar
• Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25:947–52. https://doi.org/10.1200/JCO.2006.09.7469 PMID:17350943
   PubMed Web of Science ®Google Scholar
• Milano MT, Katz AW, Schell MC, Philip A, Okunieff P. Descriptive analysis of oligometastatic lesions treated with curative intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:1516–1522. https://doi.org/10.1016/j.ijrobp.2008.03.044 PMID:18495378
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Rodari M, Bonora M, Fanti P, Fodor C, Pepe G, Lopci E, Zerini D, Vischioni B, Baroni G, et al. Orecchia [11C]choline PET/CT impacts treatment decision making in patients with prostate cancer referred for radiotherapy. R. Clin Genitourin Cancer. 2014;12(3):155–9. https://doi.org/10.1016/j.clgc.2013.11.002
   PubMed Web of Science ®Google Scholar
• Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH. Sandler H Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74. https://doi.org/10.1016/j.ijrobp.2006.04.029
   PubMed Web of Science ®Google Scholar
• Wahl RL, Jacene H, Kasamon Y. Lodge MA From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S. https://doi.org/10.2967/jnumed.108.057307
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration- resistant prostate cancer. Eur Urol. 2014;65:467–79.
   PubMed Web of Science ®Google Scholar
• Katz EE, Harding 3rd JN, Brendler C. Return of serum prostate specific antigen to undetectable level following removal of solitary lymph node metastasis. J Urol. 2002;168:2546. https://doi.org/10.1016/S0022-5347(05)64196-1 PMID:12441968
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Eto M, Ando S. Surgical excision of a metastatic adrenal lesion in a patient with prostatic cancer. Int J Urol. 1999;6:38–40. https://doi.org/10.1046/j.1442-2042.1999.06125.x PMID:10221863
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Fariselli L, Beltramo G, Catalano G, Serafini F, Garibaldi C, et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol. 2009;93(1):14–7. https://doi.org/10.1016/j.radonc.2009.04.001
   PubMed Web of Science ®Google Scholar
• Ost P, Jereczek-Fossa BA, Van As N, Zilli T, Tree A, Henderson D, Orecchia R. et al. Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol (R Coll Radiol). 2016;28(9):e115–20. https://doi.org/10.1016/j.clon.2016.04.040
   PubMed Web of Science ®Google Scholar
• Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011;97(1):49–55
   PubMed Web of Science ®Google Scholar
• Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S. et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 2013;3:1254–71. https://doi.org/10.1158/2159-8290.CD-13-0108 PMID:24027197
   PubMed Web of Science ®Google Scholar
• Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3:1245–53. https://doi.org/10.1158/2159-8290.CD-13-0172 PMID:24027196
   PubMed Web of Science ®Google Scholar
• Milosevic M, Chung P, Parke, C, Bristow R, Toi A, Panzarella T, et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: Implications for disease progression and radiation response. Cancer Res. 2007;67:6022–25 https://doi.org/10.1158/0008-5472.CAN-07-0561 PMID:17616657
   PubMed Web of Science ®Google Scholar
• Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer. 2008;8:180–92.
   PubMed Web of Science ®Google Scholar
• Milosevic M, Warde P, Menard C, Chung P, Toi A, Ishkanian A, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin. Cancer Res. 2012;18:2108–14. https://doi.org/10.1158/1078-0432.CCR-11-2711 PMID:22465832
   PubMed Web of Science ®Google Scholar
• Anscher MS. Salvage radiotherapy for recurrent prostate cancer: the earlier the better. JAMA 2004;291:1380–82. https://doi.org/10.1001/jama.291.11.1380 PMID:15026405
   PubMed Web of Science ®Google Scholar
• Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(25):67–74. https://doi.org/10.1016/j.ijrobp.2007.06.054
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500. https://doi.org/10.1016/S0360-3016(98)00091-1 PMID:9635694
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. EurUrol. 2011;59:572–83.
   Google Scholar
• Miralbell R, Vees H, Lozano J, Khan H, Mollà M, Hidalgo A, et al. Endoorectal MRI assessment of local relapse after surgery for prostate cancer: a model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys. 2007;67(2):356–61. https://doi.org/10.1016/j.ijrobp.2006.08.079
   PubMed Web of Science ®Google Scholar
• Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, Mancini M. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med. 2008;113:895–904.. https://doi.org/10.1007/s11547-008-0263-8 PMID:18414809
   PubMed Web of Science ®Google Scholar
• Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:301–309. https://doi.org/10.1007/s00259-009-1253-3 PMID:19756592
   PubMed Web of Science ®Google Scholar
• Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol. 2005;181(8):483–99. https://doi.org/10.1007/s00066-005-1422-7
   PubMed Web of Science ®Google Scholar
• Schilling D, Schlemmer HP, Wagner PH, Böttcher P, Merseburger AS, Aschoff P, et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int. 2008;102(4):446–51. https://doi.org/10.1111/j.1464-410X.2008.07592.x
   PubMed Web of Science ®Google Scholar
• Soyka JD, Muster MA, Schmid DT, Seifert B, Schick U, Miralbell R, et–al. Clinical impact of (18)F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):936–43. https://doi.org/10.1007/s00259-012-2083-2]
   PubMed Web of Science ®Google Scholar
• Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. https://doi.org/10.1007/s00259-013-2525-5]
   PubMed Web of Science ®Google Scholar